Kunwar Shailubhai
Corporate Officer/Principal at Baruch S. Blumberg Institute
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gary Jacob | M | 77 |
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 15 years |
| John Brancaccio | M | 76 |
Tiziana Life Sciences Ltd. (United Kingdom)
 Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 16 years |
| Willy Simon | M | 72 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 9 years |
| Gabriele Cerrone | M | 52 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 14 years |
| Leslie M. Magnus | F | - | 9 years | |
| Matthew Davis | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 2 years |
| Timothy Block | M | 69 |
Baruch S. Blumberg Institute
| - |
| Keeren Shah | F | 47 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 4 years |
| Ray A. Mundy | M | 79 |
University of Missouri
| 24 years |
| Jules S. Jacob | M | - | 7 years | |
| Carol Brosgart | M | 72 |
Baruch S. Blumberg Institute
| - |
| Stephen Comiskey | M | - | 16 years | |
| Michael Sofia | M | 66 |
Baruch S. Blumberg Institute
| 12 years |
| Joel Rosen | M | - |
Baruch S. Blumberg Institute
| - |
| Raj Patil | M | 66 | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bernard Denoyer | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 13 years |
| Jim Tripp | M | 54 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
| Riccardo Dalla-Favera | M | 72 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 5 years |
| Thomas H. Adams | M | 81 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 12 years |
| Troy Hamilton | M | 52 | 4 years | |
| Vaseem Palejwala | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 7 years |
| Christopher McGuigan | M | 65 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Melvin Spigelman | M | 75 | 11 years | |
| Phillip James Boyd | M | 61 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Tiziano Lazzaretti | M | 65 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 4 years |
| Alessandro Padova | M | 56 | 4 years | |
| Jim Mellon | M | 68 | 9 years | |
| Timothy Sean Callahan | M | 53 | 4 years | |
| Ben Phillips | M | - |
University of Missouri
| 6 years |
| Todd Castagno | M | - |
University of Missouri
| 5 years |
| Craig C. Talluto | M | - | - | |
| Alan F. Joslyn | M | 65 | 10 years | |
| Vishnu P. Pillay | M | 67 |
University of Baroda
| 4 years |
| Andrew Mark Gutmann | M | 54 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 3 years |
| Laura Barrow | M | - | - | |
| Richard Daly | M | 62 | 3 years | |
| Judson A. Cooper | M | 65 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Leopoldo Giampaolo Zambeletti | M | 55 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Vern Cushenbery | M | - |
University of Missouri
| 4 years |
| John Gerard Holden | M | 60 | 5 years | |
| Alex Martin Martin | M | 55 | 3 years | |
| James Mervis | M | - | - | |
| Gregor MacRae | M | 61 |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 1 years |
| Hana Malik | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | 9 years |
| Mark Gingrich | M | - |
University of Missouri
| 5 years |
| Joshua D. Schein | M | 63 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Brian Reuwee | M | - |
University of Missouri
| 4 years |
| James Matthew Shields | M | - |
University of Missouri
| 4 years |
| Andrew David Behlmann | M | - |
University of Missouri
| 4 years |
| Douglas Wulff | M | - |
University of Missouri
| 4 years |
| Erin Johnston | F | - |
University of Missouri
| 4 years |
| Reid Oyster | M | - |
University of Missouri
| 4 years |
| Andrew Michael Shenberg | M | - |
University of Missouri
| 14 years |
| Matthew Smith | M | - |
University of Missouri
| 4 years |
| Ryan Dryer | M | - |
University of Missouri
| 3 years |
| Amit Bortz | M | - |
University of Missouri
| 4 years |
| Sanjay Arun Kumar Choksi | M | 56 |
University of Baroda
| 4 years |
| Jon Althage | M | - |
University of Missouri
| 4 years |
| Greg Jones | M | - |
University of Missouri
| 4 years |
| Alison Gourley Henneberger | F | - |
University of Missouri
| 4 years |
| Paul John Cooper | M | - |
Tiziana Life Sciences Ltd. (United Kingdom)
Tiziana Life Sciences Ltd. (United Kingdom) BiotechnologyHealth Technology Tiziana Life Sciences Ltd. engages in the development of therapies for neurodegenerative and lung diseases. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
| Nick McLean | M | - |
University of Missouri
| 3 years |
| Dan Fletcher | M | - |
University of Missouri
| 4 years |
| Johanes Wargo | M | 49 |
University of Missouri
| 2 years |
| Julie Webb | F | - |
University of Missouri
| 2 years |
| Lauren Kelly Kurz | F | - |
University of Missouri
| 4 years |
| Logan Michael Purk | M | - |
University of Missouri
| 4 years |
| Keith Ecker | M | - |
University of Missouri
| 4 years |
| Jay Scott Eisenhardt | M | - |
University of Missouri
| 4 years |
| Kandarp R. Acharya | M | - |
University of Baroda
| 4 years |
| Sudhir Sahasrabudhe | M | - |
University of Baroda
| 3 years |
| Paul Hamilos | M | - |
University of Missouri
| 4 years |
| Randy M. Sternke | M | - |
University of Missouri
| 3 years |
| Amit Dilip Shah | M | 59 |
University of Baroda
| 4 years |
| Martha W. Gilliland | M | - |
University of Missouri
| 5 years |
| Gary Gemignani | M | 58 | 2 years | |
| Luke Jacobson | M | - |
University of Missouri
| 4 years |
| Christen E. Dusselier | F | 47 |
University of Missouri
| 14 years |
| Jeff Otto | M | - |
University of Missouri
| 4 years |
| Ismail Hammami | M | - |
University of Missouri
| 4 years |
| Ajoy K. Khandheria | M | - |
University of Baroda
| 5 years |
| Andrew Richard Hilgenbrink | M | - |
University of Missouri
| 4 years |
| Nick Dame | M | - |
University of Missouri
| 4 years |
| Jason Jacob Buol | M | - |
University of Missouri
| 2 years |
| Matt Kuykendall | M | - |
University of Missouri
| 3 years |
| Josh Olson | M | - |
University of Missouri
| 2 years |
| Nathan R. Burk | M | - |
University of Missouri
| 4 years |
| Linsey A. Schoemehl | F | - |
University of Missouri
| 4 years |
| Brian R. Wamhoff | M | - |
University of Missouri
| 3 years |
| D. Ryan Plasse | M | - |
University of Missouri
| 1 years |
| Travis D. Knight | M | - |
University of Missouri
| 4 years |
| Nick Withrow | M | - |
University of Missouri
| 4 years |
| John M. Lyon | M | - |
University of Missouri
| 3 years |
| Joe Rohlena | M | - |
University of Missouri
| 4 years |
| Ben Frede | M | - |
University of Missouri
| 4 years |
| Gregory P. Westrich | M | - |
University of Missouri
| 4 years |
| Nicholas Parks | M | 45 |
University of Missouri
| 4 years |
| Adam West | M | - |
University of Missouri
| 4 years |
| Tricia Nguyen | M | - |
University of Missouri
| 4 years |
| Maggie Kenefake | F | - |
University of Missouri
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 83 | 83.00% |
| Bermuda | 16 | 16.00% |
| United Kingdom | 10 | 10.00% |
| India | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kunwar Shailubhai
- Personal Network
